Jin-Jing Jia1, Wen-Shuo Geng1, Zhan-Qi Wang2, Lei Chen1, Xian-Si Zeng3. 1. Key Laboratory of Tea Plant Biology of Henan Province, College of Life Sciences, Xinyang Normal University, Xinyang, 464000, China. 2. Key Laboratory of Vector Biology and Pathogen Control of Zhejiang Province, College of Life Sciences, Huzhou University, Huzhou, 313000, China. 3. Key Laboratory of Tea Plant Biology of Henan Province, College of Life Sciences, Xinyang Normal University, Xinyang, 464000, China. xszeng@xynu.edu.cn.
Abstract
PURPOSE: Cancer, a major public health problem, exhibits significant redox alteration. Thioredoxin (Trx) system, including Trx and Trx reductase (TrxR), as well as Trx-interacting protein (TXNIP) play important roles in controlling the cellular redox balance in cancer cells. In most cancers, Trx and TrxR are usually overexpressed and TXNIP is underexpressed. In recent years, some agents targeting Trx, TrxR, and TXNIP were used to explore a therapy approach for cancer patients. METHODS: A systematic search of PMC and the PubMed Database was conducted to summarize the potential of Trx system inhibitors for cancer treatment. RESULTS: In this article, we first summarize the functions of Trx, TrxR, and TXNIP in cancers. We also review some small molecule inhibitors of Trx/TrxR and D-allose (TXNIP inducer) and discuss their antitumor mechanisms. We highlight the combined inhibition of Trx system and GSH system in cancer therapy. We expect that a highly specific and selective antitumor agent with no cytotoxicity on human normal cells could be developed in the future. CONCLUSION: In conclusion, Trx system may be very promising for clinical therapy of cancer in the future.
PURPOSE:Cancer, a major public health problem, exhibits significant redox alteration. Thioredoxin (Trx) system, including Trx and Trx reductase (TrxR), as well as Trx-interacting protein (TXNIP) play important roles in controlling the cellular redox balance in cancer cells. In most cancers, Trx and TrxR are usually overexpressed and TXNIP is underexpressed. In recent years, some agents targeting Trx, TrxR, and TXNIP were used to explore a therapy approach for cancerpatients. METHODS: A systematic search of PMC and the PubMed Database was conducted to summarize the potential of Trx system inhibitors for cancer treatment. RESULTS: In this article, we first summarize the functions of Trx, TrxR, and TXNIP in cancers. We also review some small molecule inhibitors of Trx/TrxR and D-allose (TXNIP inducer) and discuss their antitumor mechanisms. We highlight the combined inhibition of Trx system and GSH system in cancer therapy. We expect that a highly specific and selective antitumor agent with no cytotoxicity on human normal cells could be developed in the future. CONCLUSION: In conclusion, Trx system may be very promising for clinical therapy of cancer in the future.
Entities:
Keywords:
Cancer; Combined therapy; Inhibitor; Redox; Thioredoxin system
Authors: Kalishwaralal Kalimuthu; Chenicheri K Keerthana; Manikandan Mohan; Jaison Arivalagan; Johnson Retnaraj Samuel Selvan Christyraj; Michael A Firer; Mohammad Haroon Asif Choudry; Ruby John Anto; Yong J Lee Journal: J Cell Biochem Date: 2021-12-21 Impact factor: 4.429
Authors: Xue-Quan Zhou; Imma Carbo-Bague; Maxime A Siegler; Jonathan Hilgendorf; Uttara Basu; Ingo Ott; Rongfang Liu; Liyan Zhang; Vadde Ramu; Adriaan P IJzerman; Sylvestre Bonnet Journal: JACS Au Date: 2021-03-16